glp-1 for diabetes type 2 Receptor Agonists as Treatments How GLP-1 Medicines Help Manage

For many people, the body slowly adapts over time, and symptoms become less frequent or disappear completely after several weeks

Companies are more inclined to invest in closed-loop workflows that combine AI models, wet-lab infrastructure and high-throughput experimentation

Image Credit: zimmytws / Shutterstock A recent review article published in the Journal of Clinical Investigation summarized the adverse effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin receptor agonists such as tirzepatide

10.1126/scitranslmed.abe5795 [DOI] [PMC free article] [PubMed] [Google Scholar] Mehdi S